Modulators of sphingolipid signaling for the treatment of multiple sclerosis

The agonistic prodrug Fingolimod (FTY720) en-abled the first oral treatment of relapsing-remitting multiple sclerosis by modulating sphin-golipid signaling. Scientists developed novel Fingolimod non-prodrug derivatives, which re-duce the blood-brain-barrier leakage and blood T lymphocytes. Advantageously one derivative is fully active in the absence of sphingosine ki-nase 2 while exhibiting comparable activity to Fingolimod.

Further information: PDF

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0

Contact
Dr. Otmar Schöller

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.